Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06305780 · ClinicalTrials.gov registry record · Phase 2
RECOVER-AUTONOMIC Platform Protocol
A Phase 2 study, sponsored by Kanecia Obie Zimmerman.
- Completed
- Registry status
- Phase 2
- Development phase
- 381
- Enrollment target
NCT06305780 is a Phase 2 study that has completed, run by Kanecia Obie Zimmerman. The registered enrollment target is 381 participants.
The verdict
NCT06305780, a Phase 2 study, has completed, sponsored by Kanecia Obie Zimmerman.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 381 participants
- Enrollment target
Study Summary
This study is a platform protocol designed to be flexible so that it is suitable for a wide range of settings within health care systems and in community settings where it can be integrated into COVID-19 programs and subsequent treatment plans. This protocol is a prospective, multi-center, multi-arm, randomized, controlled platform trial evaluating various interventions for use in the treatment of autonomic dysfunction symptoms, including cardiovascular complications and postural orthostatic tachycardia syndrome (POTS), in PASC participants. The interventions tested will include non-pharmacologic care and pharmacologic therapies with study drugs.
Interventions
- DRUG IVIG + Coordinated Care
- DRUG IVIG Placebo + Coordinated Care
- DRUG Ivabradine + Coordinated Care
- DRUG Ivabradine Placebo + Coordinated Care
- DRUG IVIG + Usual Care
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 381 participants |
| Start Date | 2024-03-11 |
| Est. Completion | 2025-07-09 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06305780
The ClinicalTrials.gov registry entry for NCT06305780 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 381 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Kanecia Obie Zimmerman, which has 7 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which IVIG + Coordinated Care is the first listed.
NCT06305780 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT06305780 about?
NCT06305780 is a clinical study titled "RECOVER-AUTONOMIC Platform Protocol". This study is a platform protocol designed to be flexible so that it is suitable for a wide range of settings within health care systems and in community settings where it can be integrated into COVID-19 programs and subsequent treatment plans. This protocol is a prospective, multi-center, multi-ar...
What is the current status of trial NCT06305780?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 381 participants. The study started on 2024-03-11. Estimated completion is 2025-07-09.
What interventions are being tested in trial NCT06305780?
The interventions under investigation include: IVIG + Coordinated Care (DRUG), IVIG Placebo + Coordinated Care (DRUG), Ivabradine + Coordinated Care (DRUG), Ivabradine Placebo + Coordinated Care (DRUG), IVIG + Usual Care (DRUG).
Who is sponsoring clinical trial NCT06305780?
This trial is sponsored by Kanecia Obie Zimmerman, which has 7 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.